Phaseline

Companies › RHEACELL GmbH & Co. KG

RHEACELL GmbH & Co. KG: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 3; Cardiovascular, Other; next expected readout Jan 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
allo-APZ2-OTS
Allogeneic ABCB5-positive dermal mesenchymal stromal cells
ABCB5Phase 3Epidermolysis Bullosa; Venous Leg UlcerJan 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05838092allo-APZ2-OTSPhase 3Epidermolysis BullosaOtherAug 2025
NCT05464381allo-APZ2-OTSPhase 3Epidermolysis BullosaOtherJan 2027
NCT06489028allo-APZ2-OTSPhase 3Venous Leg UlcerCardiovascularApr 2027

Targets

ABCB5 (1)

Companies with the same targets

–

Companies built like this

Tenax Therapeutics Bracco Diagnostics Getz Pharma Vaderis Therapeutics Huons Biopharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.